Clinical Trial

Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer

Study acronym: DETOXp
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.
Protocol Amendment History 5 changes
critical Recruitment opened 2026-05-30
notable Primary completion pushed: 2029-08 -> 2029-09 2026-05-30
minor Completion pushed: 2030-08 -> 2030-09 2026-05-30
notable Primary completion pushed: 2029-06 -> 2029-08 2026-05-13
minor Completion pushed: 2030-06 -> 2030-08 2026-05-13
Trial Details
NCT Number NCT07109817
Lead Sponsor Montefiore Medical Center
Conditions Breast Cancer, Peripheral Neuropathy
Enrollment 116 participants
Start Date 2026-06
Primary Completion 2029-09 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-29